01—Abstract
Summary
Summary of the 8-K filed February 5, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories reported fourth quarter and full year 2023 results on February 5, 2024, closing a year of strong organic growth and margin expansion.
Q4 revenue was $902 milliona, up 9% as reported and 8% organically, with Companion Animal Group (CAG) growing 10% reported and 9% organically. CAG Diagnostics recurring revenue grew 11% reported and 10% organically, led by IDEXX VetLab consumables (+14% reported, +13% organic) on the back of 11% expansion of the global premium instrument installed base. Q4 EPS was $2.32, up 13% as reported and 17% on a comparable basis.
Full-year 2023 revenue reached $3,661 millionb (+9% reported and organic), and EPS was $10.06 (+25% reported, +29% comparable). Operating margin expanded 330 basis points as reported to 30.0%, though this was flattered by a $80 million in-license of technology in 2022 and a $16 million customer contract resolution in 2023, with the comparable benefit of roughly 280 basis points from these discrete items. For 2024, management guided to revenue of $3,930 million to $4,040 million, implying reported growth of 7.5% to 10.5% and organic growth of 7% to 10%.
CAG Diagnostics recurring revenue is expected to grow 7.5% to 10.5%, assuming an estimated 5% benefit from net price improvement. EPS guidance is $10.84 to $11.33c, representing 8% to 13% growth, though this includes roughly a 2% headwind from lapping the 2023 customer contract resolution. Operating margin is projected at 30.2% to 30.7%, a 20 to 70 basis point expansion net of a roughly 40 basis point drag from the lapping effect.
Management expects operating cash flow of 110% to 115% of net income, free cash flow of 90% to 95% of net income, and capital expenditures of about $180 milliond. Investors should weigh the strong underlying demand and pricing power in consumables and the recurring revenue base against the normalization of 2023 one-time benefits, which makes the 2024 EPS growth optically lower than the 2023 headline. Balance sheet strength improved markedly, with cash rising to $454 million and the credit facility balance falling to $250 million from $579 million a year earlier.
02—Key points
Key Highlights
- Q4 2023 revenue of $902 million grew 9% reported and 8% organically; CAG Diagnostics recurring revenue grew 11% reported and 10% organically.
- Q4 2023 EPS of $2.32 rose 13% as reported and 17% on a comparable basis; operating margin was 27.2%, down 10 bps reported but up 60 bps comparable.
- Full-year 2023 EPS of $10.06 increased 25% reported, but included a ~12% growth benefit from a $80 million technology in-license in 2022 and a $16 million customer contract resolution in 2023.
- 2024 revenue guidance of $3,930M to $4,040M implies 7.5% to 10.5% reported growth, with a ~5% benefit from net price improvement in CAG Diagnostics.
- 2024 EPS guidance of $10.84 to $11.33 implies 8% to 13% growth, with a ~2% headwind from lapping the 2023 customer contract resolution.
- Free cash flow for 2023 was $773 million, nearly double the $394 million in 2022, and cash on hand rose to $454 million while the credit facility was reduced to $250 million.
- Management expects 2024 capital expenditures of about $180 million and an effective tax rate of roughly 22%.
03—Questions
Frequently Asked Questions
How strong was IDEXX's underlying growth in Q4 2023?
Revenue grew 9% reported and 8% organically, with CAG Diagnostics recurring revenue up 11% reported and 10% organically. IDEXX VetLab consumables were the standout, growing 14% reported and 13% organically, supported by 11% growth in the global premium instrument installed base and net price gains.
Why does 2024 EPS growth look lower than 2023 growth?
The 2023 EPS growth of 25% reported and 29% comparable was boosted by a $16 million customer contract resolution in 2023 and by the lapping of a $80 million technology in-license expense in 2022. As these discrete items normalize, 2024 EPS growth is guided to 8% to 13%, including a roughly 2% negative impact from lapping the 2023 contract resolution.
What are the key assumptions behind 2024 revenue guidance?
Guidance of $3,930M to $4,040M assumes 7% to 10% organic growth and approximately 0% currency impact. CAG Diagnostics recurring revenue is expected to grow 7.5% to 10.5%, which includes an estimated 5% full-year benefit from net price improvement and continued solid volume gains from execution drivers. Acquisitions are expected to add about 50 basis points.
How is IDEXX's balance sheet and cash generation positioned?
Cash and equivalents rose to $454 million from $113 million, and the credit facility balance fell to $250 million from $579 million. 2023 operating cash flow was $907 million and free cash flow was $773 million. For 2024, management expects operating cash flow of 110% to 115% of net income and free cash flow of 90% to 95% of net income.
04—Continue